Oruka Therapeutics (NASDAQ:ORKA) Shares Cross Above 50-Day Moving Average – What’s Next?

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $89.99 and traded as high as $93.42. Oruka Therapeutics shares last traded at $90.33, with a volume of 1,942,731 shares.

Analyst Ratings Changes

Several research analysts have recently commented on ORKA shares. HC Wainwright restated a “buy” rating on shares of Oruka Therapeutics in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. Piper Sandler reiterated an “overweight” rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Finally, Wedbush reissued an “outperform” rating and set a $165.00 target price on shares of Oruka Therapeutics in a research report on Tuesday. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Oruka Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $133.00.

Oruka Therapeutics Stock Up 0.2%

The company has a 50-day moving average price of $88.89 and a 200-day moving average price of $68.23. The company has a market capitalization of $6.35 billion, a price-to-earnings ratio of -47.28 and a beta of -0.37.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Equities analysts expect that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In other news, CEO Lawrence Klein sold 25,000 shares of Oruka Therapeutics stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $83.62, for a total value of $2,090,500.00. Following the completion of the transaction, the chief executive officer owned 923,128 shares in the company, valued at approximately $77,191,963.36. The trade was a 2.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $74.81, for a total transaction of $523,670.00. Following the completion of the sale, the insider directly owned 31,771 shares of the company’s stock, valued at $2,376,788.51. The trade was a 18.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 154,950 shares of company stock worth $14,102,680 over the last three months. Company insiders own 23.49% of the company’s stock.

Institutional Trading of Oruka Therapeutics

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Oruka Therapeutics in the second quarter valued at about $474,916,000. Jupiter Topco LLC bought a new position in Oruka Therapeutics during the second quarter valued at about $130,968,000. Remedium Capital Partners LLC increased its position in Oruka Therapeutics by 0.9% in the first quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock worth $76,796,000 after buying an additional 13,247 shares during the last quarter. Avidity Partners Management LP raised its position in shares of Oruka Therapeutics by 15.1% in the first quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock valued at $37,299,000 after purchasing an additional 100,000 shares during the period. Finally, Bank of America Corp DE purchased a new stake in Oruka Therapeutics during the 2nd quarter worth about $33,578,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.